Consort and Opiant to work on nasal spray overdose treatment

Sept 10 (Reuters) - Consort Medical Plc has agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc .

Opiant earlier this year was awarded a $7.4 million grant by the National Institutes of Health’s National Institute on Drug Abuse (NIDA) for the development of a nasally-applied version of overdose treatment nalmefene. (Reporting by Noor Zainab Hussain in Bengaluru; editing by Patrick Graham)


Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.

Sign up for a free trial of our full service at and follow us on Twitter @Breakingviews and at All opinions expressed are those of the authors.